Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...

Shares of Tectonic Therapeutic (NASDAQ:TECX) added ~40% in the premarket on Thursday after the cardiac medicines developer ...

Tectonic Therapeutic said the findings support the design and population for Phase 2 APEX trial, which will test TX45 in ...

Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...

Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE:LLY) for chronic kidney disease was terminated due to a lack of foreseeable clinical benefit.

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.

Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...